Laura Housman supports clients with research and analysis that span the full spectrum of healthcare sectors and stakeholders.

She applies her background in evidence generation, commercialization and strategy to a broad range of client projects.

Before joining Avalere, Laura held a variety of leadership positions in industry and academia, including at Novartis where she led a team in access and health outcomes in support of molecular diagnostics and targeted therapies. Additionally, she founded Access Solutions Consulting, has led a national team in access, outcomes, and population health with Exact Sciences, and developed novel risk-sharing arrangements during her tenure at BlueCross BlueShield of Massachusetts.

Laura has a BA in economics, a Master of Public Health, and a Master of Business Administration from Boston University. She is currently a doctoral candidate in the School of Public Health at Boston University.

Authored Content

On March 2, 2023, the Improving Diabetes Quality Initiative (iDQI) hosted a corporate roundtable to discuss the future of diabetes care and technology.

CMMI releases long-awaited response to President Biden’s executive order on drug pricing with a directive for the Centers for Medicare & Medicaid Services (CMS) to develop three models.